[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=b249d69fbe01f6afb87f5941c08ecd6ee9d5674b873c7dd1cdd2367fc8e348ae",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740415020,
      "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "id": 132884881,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=b249d69fbe01f6afb87f5941c08ecd6ee9d5674b873c7dd1cdd2367fc8e348ae"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Gets Speedy FDA Review of Opdivo/Yervoy Combo in Certain Colorectal Cancer Patients",
    "summary": "By Colin Kellaher Bristol Myers Squibb has won Food and Drug Administration priority review for its application seeking approval of the combination of its Opdivo and Yervoy cancer drugs for the...",
    "url": "https://finnhub.io/api/news?id=bec55d02ffb30dae28ca1edf1ba1f229c4ba4e1545dbfedd998280462c4e6c38",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740382572,
      "headline": "Bristol Myers Gets Speedy FDA Review of Opdivo/Yervoy Combo in Certain Colorectal Cancer Patients",
      "id": 132862951,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Bristol Myers Squibb has won Food and Drug Administration priority review for its application seeking approval of the combination of its Opdivo and Yervoy cancer drugs for the...",
      "url": "https://finnhub.io/api/news?id=bec55d02ffb30dae28ca1edf1ba1f229c4ba4e1545dbfedd998280462c4e6c38"
    }
  },
  {
    "ts": null,
    "headline": "Don't Get Left Behind - The Great Rotation Into Dividend Stocks Is Here",
    "summary": "Dividend stocks are becoming safer bets for future returns, as highlighted by recent market analyses. Read more to see my thoughts.",
    "url": "https://finnhub.io/api/news?id=034a70d20ac9c5837dd0f6c30cea07df811a3bab178e868a2901df3a4c5fe6e5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740382200,
      "headline": "Don't Get Left Behind - The Great Rotation Into Dividend Stocks Is Here",
      "id": 132863010,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/173198842/image_173198842.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Dividend stocks are becoming safer bets for future returns, as highlighted by recent market analyses. Read more to see my thoughts.",
      "url": "https://finnhub.io/api/news?id=034a70d20ac9c5837dd0f6c30cea07df811a3bab178e868a2901df3a4c5fe6e5"
    }
  },
  {
    "ts": null,
    "headline": "U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...",
    "summary": "Application based on analyses from the Phase 3 CheckMate -8HW clinical trial, in which Opdivo plus Yervoy demonstrated superior progression-free survival compared to Opdivo monotherapy and...",
    "url": "https://finnhub.io/api/news?id=a59acae070b947f604d3cd7955cf6409bcb2c20b070f4452ddf286901b1330da",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740380404,
      "headline": "U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...",
      "id": 132862701,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Application based on analyses from the Phase 3 CheckMate -8HW clinical trial, in which Opdivo plus Yervoy demonstrated superior progression-free survival compared to Opdivo monotherapy and...",
      "url": "https://finnhub.io/api/news?id=a59acae070b947f604d3cd7955cf6409bcb2c20b070f4452ddf286901b1330da"
    }
  }
]